Large Cap Pharma Company Announces 45% Jump In Profit, Rs 8.5 Dividend

Large cap pharmaceutical sector company, Cipla Ltd on Friday reported its consolidated net profit to Rs 526 crore for the quarter ended March 31, up 45% as against Rs 362 crore announced in the year ago period. Meanwhile, revenue from operations for the quarter soared 9% YoY to Rs 5,739 crore. Board of directors of Cipla Ltd recommended a final dividend of Rs 8.50 per equity share. Check details below:

Cipla's EBITDA (earnings before interest, tax, depreciation, and amortisation) soared 54% to Rs 1,174 crore and margins improved strongly by 596 bps to 20.5%. "I am pleased to share that we continue to make significant progress across our focused markets. In FY23, we recorded the highest-ever revenue with EBITDA crossing Rs 5,000 crore for the first time. We are excited for the upcoming year, where we look forward to deepening our leadership in branded markets and expanding our differentiated pipeline in the US," said Umang Vohra MD and Global CEO, Cipla.

Cipla Ltd Declares Dividend: According to the exchange filing of the pharma company, "The Board of Directors also recommended the payment of a final dividend of Rs. 8.50/- per equity share (face value of Rs. 2/- per equity share) for the financial year ended 31st March 2023. The dividend, upon approval by the shareholders, will be paid to shareholders within 30 days from the date of the Annual General Meeting."

Cipla Ltd Stock Performance & Return: The last trading price of Cipla on BSE is Rs 934.90 per share with intraday fall of 0.93%. The stock's 52-week high price is Rs 1185.20 per share and 52-week low price is Rs 852.00 per share, respectively. Its market capitalisation is Rs 75,461.12 crore.
The stock gave over 1% return in last 1-year, 4% return in last 2-years, and 64% return in last 3-years.

Cipla Ltd About: Cipla is a leading pharmaceutical company that provides affordable medicine to patients across geographies. It came into existence in 1935.